Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

Type
Public
HQ
Petaluma, US
Size (employees)
38 (est)+12%
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is headquartered in Petaluma, US

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Office Locations

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) has offices in Petaluma, Herten
Petaluma, US (HQ)
1129 N McDowell Blvd
Herten, NL
6049 LX Herten/Roermond

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Metrics

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Financial Metrics

Revenue (2016)

$15.1 m

Revenue growth (2015-16), %

9%

Gross profit

$7.2 m

Gross profit margin (2016), %

48%

Net income (2016)

($10.2 m)

Market capitalization (05-Dec-2016)

$20.9 m

Closing share price (05-Dec-2016)

$4.9

Cash (31-Mar-2016)

$7.5 m
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s current market capitalization is $20.9 m.
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s revenue was reported to be $15.1 m in FY, 2016 which is a 8.9% increase from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

$13.7 m$13.9 m$15.1 m

Revenue growth, %

1%9%

Cost of goods sold

$5.3 m$6.6 m$7.9 m

Gross profit

$8.4 m$7.3 m$7.2 m

Gross profit Margin, %

61%53%48%

Operating expense total

$14.4 m$13.9 m$17.4 m

EBIT

($6.1 m)($6.7 m)($10.2 m)

EBIT margin, %

(44%)(48%)(67%)

Interest expense

$1.1 m$3 k$3 k

Interest income

$1 k$1 k$2 k

Net Income

$3.7 m($8.2 m)($10.2 m)
FY, 2014FY, 2015FY, 2016

Cash

$5.5 m$6.1 m$7.5 m

Accounts Receivable

$1.8 m$1.5 m$2.3 m

Inventories

$647 k$592 k$1.5 m

Current Assets

$9.5 m$9.6 m$12.9 m

PP&E

$971 k$795 k$850 k

Total Assets

$20.8 m$15 m$13.8 m

Accounts Payable

$736 k$932 k$1.3 m

Current Liabilities

$7.6 m$2.6 m$3.6 m

Additional Paid-in Capital

$149.1 m$157.8 m$166.4 m

Retained Earnings

($134 m)($142.2 m)($152.4 m)

Total Equity

$12.1 m$12.1 m$10.1 m

Financial Leverage

1.7 x1.2 x1.4 x
FY, 2014FY, 2015FY, 2016

Net Income

$3.7 m($8.2 m)($10.2 m)

Depreciation and Amortization

$284 k$253 k$244 k

Accounts Receivable

($88 k)$40 k($1.3 m)

Inventories

($126 k)($627 k)($382 k)

Accounts Payable

$848 k$222 k$429 k

Cash From Operating Activities

($4.9 m)($6.7 m)($8.7 m)

Purchases of PP&E

($504 k)($139 k)($345 k)

Cash From Investing Activities

($445 k)$875 k$4.2 m

Long-term Borrowings

($1.6 m)($176 k)($119 k)

Interest Paid

$195 k$3 k$3 k

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Market Value History

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Company Life

You may also be interested in